Glurenorm

Quick links to important sections

Glurenorm

Selected form

Method of action: Hypoglycemic

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glurenorm

Quick Facts

Property Description
Active ingredient Gliquidone (INN)
Form Tablet
Pharmacological class Oral Hypoglycemic Agent
Common purpose Blood glucose-lowering
Origin Synthetic compound

What Type of Medicine is Glurenorm (Gliquidone)?

Glurenorm is a prescription-only medicine whose active ingredient is Gliquidone, and it is fundamentally classified as an Oral Hypoglycemic Agent. This drug is used in the metabolic management of high blood sugar in patients with Type 2 Diabetes Mellitus.

Gliquidone is a synthetic compound that belongs to the sulfonylurea derivative class of drugs. It is recognized as a second-generation sulfonylurea. Its general therapeutic purpose, therefore, aligns with its category as an antidiabetic drug: to achieve systemic blood glucose-lowering control, typically used when dietary changes alone prove insufficient.

Composition, Origin, and Pharmaceutical Form

Glurenorm is manufactured primarily as a tablet pharmaceutical preparation intended for oral administration. The product is a single-active ingredient product, featuring only Gliquidone as the therapeutically active compound. The physical form of the medicine consists of the Gliquidone active ingredient combined with necessary solid pharmaceutical excipients that establish the stable structure for the tablet.

The Role of Glurenorm: General Purpose and Core Action

The general role of Glurenorm is to provide essential blood glucose-lowering support for adult patients. The action that defines this Oral Hypoglycemic Agent is its ability to promote insulin release stimulation directly from the pancreas, a mechanism that is clinically recognized for effectively reducing hyperglycemia. This secretagogue action helps ensure that the body is assisted in utilizing its own insulin reserves to manage glucose levels effectively, which is the foundational goal for managing Type 2 Diabetes Mellitus.

Regulatory References

  1. Glurenorm Product Information (HALMED)
  2. Sulfonylureas Overview (NIH/NCBI)

What side effects are possible with Glurenorm?

Possible Side Effects and Safety Information

Glurenorm (gliquidone) is associated with an official safety profile primarily defined by its effects on blood glucose levels and documented reactions across various body systems. This information is based strictly on government regulatory documents.

Primary and Serious Adverse Reactions

The most common adverse reaction documented for Glurenorm is Hypoglycemia (low blood sugar), which is expected due to the medicine's mechanism.

Serious Adverse Reactions that are rare but clinically significant include:

  • Severe Hypoglycemia: Episodes that may lead to loss of consciousness or seizures.
  • Blood Dyscrasias: Severe abnormalities in blood cell counts, such as agranulocytosis (a serious reduction in white blood cells) or thrombocytopenia.
  • Hepatic Dysfunction: Serious effects on the liver, including the potential for cholestatic jaundice.

System-Organ-Class Reactions

Adverse reactions are formally categorized by the affected body system in regulatory documentation:

System-Organ Class Example Reactions (Common to Rare)
Metabolism and Nutrition Hypoglycemia
Gastrointestinal Nausea, vomiting, abdominal discomfort
Skin and Subcutaneous Allergic reactions, such as rash or pruritus
Blood and Lymphatic Leukopenia, mild or severe blood cell count changes

Safety Restrictions and Population Notes

The use of Glurenorm is subject to specific regulatory restrictions and safety notes:

  • Contraindications: The medicine is officially contraindicated in patients with Type 1 Diabetes Mellitus, Diabetic Ketoacidosis, and in cases of severe hepatic or renal impairment.
  • Pregnancy and Lactation: Use is generally not recommended due to the risk of low blood sugar in the fetus or newborn.
  • Renal Function: Glurenorm is often noted in regulatory summaries as an option for patients with mild to moderate renal insufficiency because it is primarily excreted through the bile and feces.

The regulatory safety structure underscores the importance of blood glucose monitoring, as the risk of low blood sugar may be higher when treatment is first started or when the dose is adjusted.

Overdose and Emergency Response

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations: The primary manifestation is profound and prolonged hypoglycemia, which may present with confusion, agitation, tremor, sweating, anxiety, and nausea.
Physiological systems affected: The Central Nervous System (CNS), resulting in altered mental status and seizures, and the Cardiovascular system, resulting in rapid heartbeat (tachycardia).
Dose-related or exposure-related factors: Ingestion of a single tablet by a child is cited as a significant exposure risk that may cause prolonged hypoglycemia.
When immediate medical help is required: Immediate medical attention is required for all intentional overdoses and any patient exhibiting symptoms of hypoglycemia or who may have had a serious exposure.

Overdose classifications (high-level)

Classification Detail Official Regulatory Statement
Severity classification: Overdose is classified as potentially severe or life-threatening due to the risk of irreversible outcomes, including coma, convulsions, permanent brain damage, and death if left untreated.
Emergency-response statements: Call the local emergency number or Poison Control Center immediately for instruction. Prolonged hospital monitoring is necessary, often for 24 hours or more.

Connection to the overall overdose profile

Regulatory documents define the Glurenorm overdose profile based on its core action, which leads to prolonged hypoglycemia as the critical event. This necessitates that all cases involving symptomatic overdose or significant exposure require immediate contact with emergency services and prolonged hospital monitoring with supportive treatment measures such as intravenous glucose.

Therapeutic Uses of Glurenorm

Glurenorm (gliquidone) is a medication primarily relevant for conditions characterized by periods of heightened symptoms related to impaired glucose metabolism. Its main therapeutic domain involves the management of Type 2 Diabetes Mellitus. This condition is marked by the body's inability to properly regulate blood sugar, leading to systemic imbalance.

This medicine is applied in scenarios where dietary measures and physical activity alone are not sufficient to help with carbohydrate metabolism. It is commonly used when supportive symptom management is appropriate, assisting with easing the symptom of high blood sugar. The primary indications are Type 2 Diabetes Mellitus, generally focusing on managing the condition when it involves episodic or fluctuating manifestations.

Glurenorm supports the patient during difficult episodes by easing distress related to glucose imbalance and may assist with maintaining a more stable physiological state during symptomatic periods associated with this chronic condition. It provides support that helps ease the overall symptom burden and may assist with maintaining functional stability.


Quick Fact: Relief for Symptoms related to systemic imbalance

Eligibility and Restrictions for Use

Who Can and Cannot Use Glurenorm?

This section summarizes the population eligibility rules for Glurenorm (gliquidone) as defined in official government regulatory documents.


Eligible and Ineligible Populations

Classification Eligible Population Contraindicated/Ineligible Population
Disease Status Adult patients with Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus or Diabetic Ketoacidosis
Age Group Adults only Pediatric Population (use not established)
Physiological State N/A Pregnancy and Lactation (Breastfeeding)
Comorbidity Mild-to-Moderate Renal Impairment (permitted) Severe Liver Disease or Hepatic Insufficiency

Absolute Contraindications and Restrictions

Use of Glurenorm is strictly contraindicated if a patient has a known hypersensitivity to gliquidone, other sulfonylureas, or sulfonamide derivatives. The medicine must not be used in cases of Acute Porphyria or by patients who have had a pancreatectomy. Eligibility is also restricted during acute medical stress, such as severe infections or major surgical procedures, requiring temporary suspension and substitution with insulin therapy.

What should I know about interactions with other medicines?

Glurenorm Interactions with other medicines and products

The interaction profile for Glurenorm (gliquidone) is documented by regulatory authorities and details combinations that significantly alter its blood glucose lowering effect. All interaction statements are derived strictly from official government labeling.


Formal Regulatory Prohibition

The co-administration of Miconazole (systemic route or oromucosal gel) is formally contraindicated with Glurenorm. This combination is strictly prohibited because it severely potentiates the drug’s blood glucose lowering action, which carries a significant risk of severe hypoglycemia.


Agents that Increase the Blood Glucose Lowering Effect

Several medicinal products and substances are documented to reinforce the drug's action, increasing the risk of low blood sugar. This potentiation is observed with Alcohol (ethanol), which may cause a pronounced and prolonged effect. Beta-blockers are documented to reinforce this action and may also mask the typical physical warning signs of hypoglycemia. Furthermore, agents such as Phenylbutazone and certain antibiotics like Chloramphenicol are listed as increasing the exposure or effect of Glurenorm.


Agents that Reduce the Blood Glucose Lowering Effect

Certain medications may reduce the therapeutic effect of Glurenorm through antagonistic action. These include Corticosteroids (Glucocorticoids) and Thiazide Diuretics, both of which can induce hyperglycemia and reduce the overall efficacy of the antidiabetic treatment. Danazol is also documented as potentially diminishing Glurenorm's effect.


Population-Specific Interaction Note

Regulatory documentation notes that Glurenorm is almost entirely metabolized by the liver and eliminated primarily via the bile. Due to this specific clearance mechanism, the official label does not specify a mandatory restriction or dose adjustment in patients with severe renal impairment.

Mechanism of Action

Targeting the K ATP Channel for Secretagogue Action

Gliquidone's mechanism is anchored by its precise binding to the Sulfonylurea Receptor 1 ( SUR1) subunit of the ATP-sensitive Potassium Channel ( K ATP) on pancreatic beta-cells. This interaction functions as a channel blocker, inhibiting the efflux of Potassium ions ( K^+), which immediately triggers the electrical depolarization of the cell membrane. This targeted molecular action initiates the subsequent secretory cascade.

Cellular Cascade Leading to Insulin Secretion

The resulting membrane depolarization opens adjacent Voltage-Gated Ca^2+ Channels, causing a rapid influx of Calcium ions ( Ca^2+) into the beta-cell. This elevated intracellular Ca^2+ concentration drives the exocytosis of stored Insulin granules, resulting in a rise in the systemic concentration of Insulin.

Consequence of Insulin Release on Glucose Metabolism

The elevated level of circulating Insulin promotes the transfer of glucose into peripheral tissues and concurrently affects the suppression of glucose production by the liver. This integrated sequence of events results in a final physiological alteration: a lowering of glucose concentration within the systemic circulation.

Dosage and Administration Information

How to Use Glurenorm

Glurenorm (Gliquidone) is an oral hypoglycemic agent administered solely by the oral route in the form of a 30 mg tablet. Administration guidelines define specific usage patterns regarding dose, frequency, and timing relative to meals to standardize treatment.

Official Dosing and Administration

The dosage regimen involves initial, maintenance, and maximum limits, which are subject to titration based on patient response.

Dosing Parameter Official Guideline
Route & Form Oral, as a 30 mg Tablet
Initial Dose 15 mg daily (half tablet)
Maintenance Range 45 mg to 60 mg daily
Maximum Daily Dose 180 mg

Administration Protocol

Frequency and Timing

Administration begins with the 15 mg initial dose, which is taken once daily. This dose must be administered 30 minutes before breakfast. If the dose is subsequently increased above 60 mg per day, the total daily amount must be divided into two to three separate administrations, with each portion taken before a meal.

Dosing for Specific Populations

In patients with mild to moderate renal insufficiency, Glurenorm's dosing generally does not require mandatory adjustment because the drug is primarily metabolized by the liver, with only about 5% of the active substance excreted via the kidneys.

Handling Missed Doses

If a dose of Glurenorm is missed, it is advised against taking a double dose to compensate. Patients are instructed to continue with the next scheduled dose at the usual time.

Recent Clinical Evidence

Research Evidence Overview for Glurenorm (Gliquidone)

This section summarizes the official clinical research and regulatory findings that describe how Glurenorm (Gliquidone) was studied. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.


Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

Research exploring Glurenorm was studied for Type 2 Diabetes Mellitus (T2DM) consists primarily of short- to intermediate-term controlled clinical trials and older Randomized Controlled Trials (RCTs). These studies was evaluated in adult patients, including those newly starting oral therapy. Researchers examined changes in blood sugar markers, such as Glycated Hemoglobin (HbA1c), as well as shifts in Fasting Plasma Glucose (FPG) and Postprandial Plasma Glucose (PPG). Studies also examined other metabolic measures, including shifts in body weight and plasma lipid profiles during the observation periods.

The trials reported measurements of decreases in the levels of HbA1c, FPG, and PPG in the observed populations. However, long-term effects are not fully established regarding patient-related outcomes, such as the impact on cardiovascular events or mortality, as follow-up durations were limited in many of the core studies.


Studies Focused on Patients with Mild to Moderate Renal Impairment

Studies have explored the use of Glurenorm in diabetic patients who also have pre-existing mild to moderate kidney issues. This research was conducted because the body's method for removing a medicine may be influenced by kidney function. The evidence here is supported less by large-scale RCTs and more by systematic reviews and clinical observation reports.

The research explored the medicine's metabolic profile regarding its excretion pathway. Findings reported measurements of glycemic control in the observed populations with mild to moderate kidney impairment. However, evidence is limited to supporting use in individuals with severe kidney impairment. Research largely relies on the findings related to the drug’s excretion pathway and clinical observational data.


Key Limitations and Areas of Research Uncertainty

Systematic reviews indicate that the methodological quality of many older Gliquidone clinical trials was observed in some studies to be a limiting factor. There is limited information for long-term outcomes that track major clinical events or patient quality of life; the majority of reported changes relate to surrogate endpoints (biomarkers). Comparative evidence showing Glurenorm’s patterns against all newer classes of antidiabetic drugs is lacking. Research provides context, but it highlights what is known — and what is still uncertain about the medicine's profile.

Key Studies & References

  1. Antidiabetic drugs and kidney disease - Swiss Medical Weekly (Used for renal impairment profile/comparison)
  2. Comparison of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis (Used for general T2DM outcomes and comparative evidence gaps)
  3. Gliquidone – Knowledge and References (Used for general drug class context and renal elimination pathway)

Frequently Asked Questions (FAQ)

Common questions about Glurenorm (FAQ)


Q: How long does it usually take to feel the effect of Glurenorm?

A: Clinical pharmacokinetic data describes the onset of action for Glurenorm (Gliquidone) as occurring within approximately 1 to 1.5 hours after it is administered. This timing reflects the medicine’s profile in the body as it begins to stimulate insulin release.


Q: Does Glurenorm interact with blood pressure medications?

A: Official product information reports that Glurenorm can interact with certain blood pressure medicines. These include agents such as beta-blockers and ACE inhibitors. Regulatory documents note that this combination may increase the risk of low blood sugar (hypoglycemia).


Q: What is the typical expectation for blood sugar changes while on Glurenorm?

A: Studies examined the medicine's effect by reporting measurements of decreases in key markers of blood sugar control in the observed patient populations. These markers include Glycated Hemoglobin (HbA1c), Fasting Plasma Glucose, and Postprandial Plasma Glucose.


Q: Is Glurenorm known to cause skin reactions or rashes?

A: Adverse reaction data from official sources lists effects on the Skin and Subcutaneous tissue. These officially reported reactions include instances of rash and pruritus (itching).


Q: What are the signs of an allergic reaction to Glurenorm?

A: Official safety information suggests consulting a healthcare professional if symptoms are experienced. Documented signs that may be associated with hypersensitivity include a fever, a persistent skin rash, or sudden-onset nausea.


Q: Is Glurenorm a type of insulin?

A: No, Glurenorm is not insulin itself. It is classified as an Oral Hypoglycemic Agent and belongs to the sulfonylurea class of medicines. Its mechanism is to stimulate the release of the body's own insulin from the pancreas.


Q: How does Glurenorm differ from other common diabetes medicines?

A: Glurenorm is classified as a sulfonylurea derivative, meaning it works primarily by stimulating the pancreas to release insulin. This mechanism distinguishes it from other classes of diabetes drugs that may primarily reduce glucose absorption or affect insulin sensitivity.


Q: How is Glurenorm different from Metformin?

A: Glurenorm is classified as a sulfonylurea, and its core action is to stimulate the pancreas to release insulin. Metformin is typically classified as a biguanide, and it primarily works by reducing glucose production by the liver and improving the body’s sensitivity to insulin.


Q: Does taking Glurenorm affect my liver function test results?

A: Regulatory safety information notes that serious adverse reactions associated with the medicine may include effects on the liver. These officially documented effects include Hepatic Dysfunction and the potential for cholestatic jaundice (a type of liver-related yellowing).


Q: Can Glurenorm affect my ability to drive?

A: The risk of low blood sugar (hypoglycemia) may affect a person's ability to concentrate, think clearly, and react. Regulatory documents advise patients to be aware of the signs of low blood sugar, especially when driving or operating machinery.


Q: Are headaches a known side effect of Glurenorm?

A: Yes, official adverse reaction documents list headache among the possible side effects reported during the use of Glurenorm.


Q: Do any studies look at the long-term safety of Glurenorm?

A: The official research overview notes that while studies measured short- to intermediate-term effects, the long-term effects are not fully established regarding patient outcomes, such as the impact on cardiovascular events. Follow-up durations in many of the core studies were limited.


Q: Why is Glurenorm sometimes taken with food?

A: The drug's administration protocol specifies that the dose is to be taken before a meal (such as before breakfast or divided doses before other meals). This specific timing relative to eating is a regulated condition of use outlined in administration guidelines.

How should Glurenorm be stored and disposed of?

Glurenorm (gliquidone) tablets must be stored according to mandatory regulatory requirements to ensure product quality and safety.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Do not store at a temperature exceeding 30 C (approximately 86 F).
Protection Keep the product in the original package to protect it from moisture.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Glurenorm must be disposed of properly according to official guidelines.

  • Disposal must be in accordance with local requirements.
  • The medicine must not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glurenorm found in:

A-Z Index: